Compare Eli Lilly And Co (LLY) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard High Dividend Yield ETF — how do they compare? Eli Lilly And Co trades at $1,173.56 (market cap $1.04T), while Vanguard High Dividend Yield ETF trades at $158.87 (market cap $100.80B). The key difference: Eli Lilly And Co is far larger — about 10.3× Vanguard High Dividend Yield ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard High Dividend Yield ETF for 139 Days on average.
| LLY | VYM | |
|---|---|---|
Market Cap | $1.04T | $100.80B |
Volume | 3,064,878 | 908,176 |
Sector | Health | — |
52-Week High | $1.28K | $167.03 |
52-Week Low | $799.57 | $137.47 |
Typical Hold Time | 93 Days | 139 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
VYM trades at $158.76, up 0.83% with a bearish technical signal. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD. Support levels cluster near $156-157, while resistance sits at $159-160. Recent news questions VYM's stock selection methodology after dividend cuts in holdings like Intel and Walgreens.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include concentrated exposure to dividend-cut vulnerabilities and inflation persistence. Opportunities lie in Vanguard's low-cost, diversified approach for income-focused investors, though superior total return potential exists elsewhere.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
